These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 24412222)

  • 1. Treating enhanced GABAergic inhibition in Down syndrome: use of GABA α5-selective inverse agonists.
    Martínez-Cué C; Delatour B; Potier MC
    Neurosci Biobehav Rev; 2014 Oct; 46 Pt 2():218-27. PubMed ID: 24412222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reducing GABAergic inhibition restores cognitive functions in a mouse model of Down syndrome.
    Potier MC; Braudeau J; Dauphinot L; Delatour B
    CNS Neurol Disord Drug Targets; 2014 Feb; 13(1):8-15. PubMed ID: 24152333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective inhibition of extra-synaptic α5-GABA
    Etherington LA; Mihalik B; Pálvölgyi A; Ling I; Pallagi K; Kertész S; Varga P; Gunn BG; Brown AR; Livesey MR; Monteiro O; Belelli D; Barkóczy J; Spedding M; Gacsályi I; Antoni FA; Lambert JJ
    Neuropharmacology; 2017 Oct; 125():353-364. PubMed ID: 28807671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specific targeting of the GABA-A receptor α5 subtype by a selective inverse agonist restores cognitive deficits in Down syndrome mice.
    Braudeau J; Delatour B; Duchon A; Pereira PL; Dauphinot L; de Chaumont F; Olivo-Marin JC; Dodd RH; Hérault Y; Potier MC
    J Psychopharmacol; 2011 Aug; 25(8):1030-42. PubMed ID: 21693554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reducing GABAA α5 receptor-mediated inhibition rescues functional and neuromorphological deficits in a mouse model of down syndrome.
    Martínez-Cué C; Martínez P; Rueda N; Vidal R; García S; Vidal V; Corrales A; Montero JA; Pazos Á; Flórez J; Gasser R; Thomas AW; Honer M; Knoflach F; Trejo JL; Wettstein JG; Hernández MC
    J Neurosci; 2013 Feb; 33(9):3953-66. PubMed ID: 23447605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-term treatment with the GABAA receptor antagonist pentylenetetrazole produces a sustained pro-cognitive benefit in a mouse model of Down's syndrome.
    Colas D; Chuluun B; Warrier D; Blank M; Wetmore DZ; Buckmaster P; Garner CC; Heller HC
    Br J Pharmacol; 2013 Jul; 169(5):963-73. PubMed ID: 23489250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. γ-Aminobutyric acid type A (GABA(A)) receptor subtype inverse agonists as therapeutic agents in cognition.
    Gabriella G; Giovanna C
    Methods Enzymol; 2010; 485():197-211. PubMed ID: 21050918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The GABA
    Block A; Ahmed MM; Rueda N; Hernandez MC; Martinez-Cué C; Gardiner KJ
    Neuroscience; 2018 Feb; 372():192-212. PubMed ID: 29292072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic pentylenetetrazole but not donepezil treatment rescues spatial cognition in Ts65Dn mice, a model for Down syndrome.
    Rueda N; Flórez J; Martínez-Cué C
    Neurosci Lett; 2008 Mar; 433(1):22-7. PubMed ID: 18226451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained treatment with an α5 GABA A receptor negative allosteric modulator delays excitatory circuit development while maintaining GABAergic neurotransmission.
    Nuwer JL; Brady ML; Povysheva NV; Coyne A; Jacob TC
    Neuropharmacology; 2021 Oct; 197():108724. PubMed ID: 34284042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RO4938581, a novel cognitive enhancer acting at GABAA alpha5 subunit-containing receptors.
    Ballard TM; Knoflach F; Prinssen E; Borroni E; Vivian JA; Basile J; Gasser R; Moreau JL; Wettstein JG; Buettelmann B; Knust H; Thomas AW; Trube G; Hernandez MC
    Psychopharmacology (Berl); 2009 Jan; 202(1-3):207-23. PubMed ID: 18936916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence for the participation of peripheral α5 subunit-containing GABAA receptors in GABAA agonists-induced nociception in rats.
    Bravo-Hernández M; Feria-Morales LA; Torres-López JE; Cervantes-Durán C; Delgado-Lezama R; Granados-Soto V; Rocha-González HI
    Eur J Pharmacol; 2014 Jul; 734():91-7. PubMed ID: 24726872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. L-655,708 enhances cognition in rats but is not proconvulsant at a dose selective for alpha5-containing GABAA receptors.
    Atack JR; Bayley PJ; Seabrook GR; Wafford KA; McKernan RM; Dawson GR
    Neuropharmacology; 2006 Nov; 51(6):1023-9. PubMed ID: 17046030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a novel, selective GABA(A) alpha5 receptor inverse agonist which enhances cognition.
    Chambers MS; Atack JR; Broughton HB; Collinson N; Cook S; Dawson GR; Hobbs SC; Marshall G; Maubach KA; Pillai GV; Reeve AJ; MacLeod AM
    J Med Chem; 2003 May; 46(11):2227-40. PubMed ID: 12747794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Behavioural pharmacology of the α5-GABA
    Gacsályi I; Móricz K; Gigler G; Wellmann J; Nagy K; Ling I; Barkóczy J; Haller J; Lambert JJ; Szénási G; Spedding M; Antoni FA
    Neuropharmacology; 2017 Oct; 125():30-38. PubMed ID: 28694097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-lasting correction of in vivo LTP and cognitive deficits of mice modelling Down syndrome with an α5-selective GABA
    Duchon A; Gruart A; Albac C; Delatour B; Zorrilla de San Martin J; Delgado-García JM; Hérault Y; Potier MC
    Br J Pharmacol; 2020 Mar; 177(5):1106-1118. PubMed ID: 31652355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of the imidazo[1,5-a][1,2,4]-triazolo[1,5-d][1,4]benzodiazepine scaffold as a novel, potent and selective GABA(A) alpha5 inverse agonist series.
    Achermann G; Ballard TM; Blasco F; Broutin PE; Büttelmann B; Fischer H; Graf M; Hernandez MC; Hilty P; Knoflach F; Koblet A; Knust H; Kurt A; Martin JR; Masciadri R; Porter RH; Stadler H; Thomas AW; Trube G; Wichmann J
    Bioorg Med Chem Lett; 2009 Oct; 19(19):5746-52. PubMed ID: 19726184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deficits in cognition and synaptic plasticity in a mouse model of Down syndrome ameliorated by GABAB receptor antagonists.
    Kleschevnikov AM; Belichenko PV; Faizi M; Jacobs LF; Htun K; Shamloo M; Mobley WC
    J Neurosci; 2012 Jul; 32(27):9217-27. PubMed ID: 22764230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term memory impairment after isoflurane in mice is prevented by the α5 γ-aminobutyric acid type A receptor inverse agonist L-655,708.
    Saab BJ; Maclean AJ; Kanisek M; Zurek AA; Martin LJ; Roder JC; Orser BA
    Anesthesiology; 2010 Nov; 113(5):1061-71. PubMed ID: 20966663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel GABA(A) alpha 5 receptor inhibitor with therapeutic potential.
    Ling I; Mihalik B; Etherington LA; Kapus G; Pálvölgyi A; Gigler G; Kertész S; Gaál A; Pallagi K; Kiricsi P; Szabó É; Szénási G; Papp L; Hársing LG; Lévay G; Spedding M; Lambert JJ; Belelli D; Barkóczy J; Volk B; Simig G; Gacsályi I; Antoni FA
    Eur J Pharmacol; 2015 Oct; 764():497-507. PubMed ID: 26169564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.